Xeris Biopharma Holdings (XERS) FCF Margin (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly FCF Margin came in at 11.87% in Q1 2026, up 2856.0% YoY from 0.4% in Q1 2025, and down 49.17% on a QoQ basis from 23.36% in Q4 2025.
Xeris Biopharma Holdings (XERS) FCF Margin (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of FCF Margin data on file, last reported at 11.87% in Q1 2026.
- Quarterly FCF Margin rose 2856.0% year-over-year to 11.87% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 15.41% (up 2741.0% YoY) and the FY2025 annual result came in at 9.81%, up 2802.0% from the prior year.
- FCF Margin declined to 11.87% in Q1 2026, from 23.36% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 24.78% in Q3 2025 to a low of 219.31% in Q1 2022.
- A 5-year average of 33.96% and a median of 21.53% in 2024 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin jumped 14471 bps — and 2024, when it plunged 1354 bps.
- Tracing XERS's FCF Margin over 5 years: stood at 48.63% in 2022, then surged by 135 bps to 16.83% in 2023, then plunged by 80 bps to 3.29% in 2024, then jumped by 611 bps to 23.36% in 2025, then slumped by 49 bps to 11.87% in 2026.
- The last three FCF Margin figures came in at 11.87% (Q1 2026), 23.36% (Q4 2025), and 24.78% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 7.41% |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 21.80% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 14.87% |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 26.25% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 8.76% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 13.41% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 17.84% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.50 Bn | 1.38 Bn | 79.59 Mn | 8.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.97% |
| Mar 31, 2026 | 11.87% |
| Dec 31, 2025 | 23.36% |
| Sep 30, 2025 | 24.78% |
| Jun 30, 2025 | 0.25% |
| Mar 31, 2025 | -16.69% |
| Dec 31, 2024 | 3.29% |
| Sep 30, 2024 | -15.30% |
| Jun 30, 2024 | -21.53% |
| Mar 31, 2024 | -49.96% |
| Dec 31, 2023 | 16.83% |
| Sep 30, 2023 | -30.24% |
| Jun 30, 2023 | -36.16% |
| Mar 31, 2023 | -78.74% |
| Dec 31, 2022 | -48.63% |
| Sep 30, 2022 | -59.73% |
| Jun 30, 2022 | -81.44% |
| Mar 31, 2022 | -219.31% |
| Dec 31, 2021 | -135.69% |
| Sep 30, 2021 | -204.44% |